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Aims Lowpulse pressure is amarker of adverse outcome in patientswith heart failure (HF) and reduced ejection fraction (HF-
REF) but the prognostic value of pulse pressure in patientswithHF and preserved ejection fraction (HF-PEF) is unknown.
We examined the prognostic value of pulse pressure in patients withHF-PEF [ejection fraction (EF) ≥ 50%] andHF-REF.
Methods
and results
Data from 22HF studies were examined. Preserved left ventricular ejection fraction (LVEF) was defined as LVEF ≥ 50%.
All-cause mortality at 3 years was evaluated in 27 046 patients: 22 038 with HF-REF (4980 deaths) and 5008 with HF-
PEF (828 deaths). Pulse pressure was analysed in quintiles in a multivariable model adjusted for the previously reported
Meta-Analysis Global Group in Chronic Heart Failure prognostic variables. Heart failure and reduced ejection fraction
patients in the lowest pulse pressure quintile had the highest crude and adjusted mortality risk (adjusted hazard ratio
1.68, 95% confidence interval 1.53–1.84) compared with all other pulse pressure groups. For patients with HF-PEF,
higher pulse pressure was associated with the highest crude mortality, a gradient that was eliminated after adjustment
for other prognostic variables.
Conclusion Lower pulse pressure (especially ,53 mmHg) was an independent predictor of mortality in patients with HF-REF,
particularly in those with an LVEF, 30% and systolic blood pressure ,140 mmHg. Overall, this relationship
between pulse pressure and outcome was not consistently observed among patients with HF-PEF.
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Introduction
Elevated pulse pressure is an establishedmarker of adverse outcome
in healthy individuals as well as patients with certain types of cardio-
vascular disease, especially those with hypertension.1–3 More re-
cently, lower pulse pressure has emerged as an independent
predictor of mortality in patients with heart failure (HF).4–9 This
has been demonstrated in patients across the spectrum of symptom
severity, and in patients with acute as well as chronic HF. However,
studies to date have included only patients with heart failure and
reduced left ventricular ejection fraction (HF-REF). Patients with
heart failure and preserved left ventricular ejection fraction
(HF-PEF) more often have a history of hypertension than patients
with HF-REF, and therefore, may be more likely to have an elevated
pulse pressure. However, the range of pulse pressures in patients
withHF-PEF, comparedwithHF-REF, is unknown, as is the prognostic
importance of pulse pressure in HF-PEF.
We used data from 22 HF studies included in the Meta-Analysis
Global Group in Chronic Heart Failure (MAGGIC) to explore
these questions.
Methods
Study design
The design and results of the MAGGIC meta-analysis are described
elsewhere.10 Briefly, observational studies and randomized controlled
trials of patientswith establishedHFpublishedup to2008were identified
via online databases using the keywords: prognosis, outcome, HF, left
ventricle, and preserved. Studies were included if they enrolled patients
with HF, reported outcome (all-cause mortality), and did not use left
ventricular ejection fraction (LVEF) as criterion for entry to the study.
TheUniversityofAucklandHumanSubjects EthicsCommittee approved
the original meta-analysis and the study compliedwith theDeclaration of
Helsinki. All patients providedwritten informed consent to participate in
the individual studies.
Of 56 potential studies that were identified, investigators from 31
studies provided data on a pre-defined set of variables including demo-
graphics, medical history, medical treatment, symptom status, clinical
variables, laboratory variables, and duration of follow-up. All-cause
death was the only outcome available. Preserved LVEF was defined as
≥50%. Blood pressure (BP) measurement was taken over the brachial
artery with a standard sphygmomanometer and recorded at the baseline
study visit (at an outpatient visit, at randomization, or during hospitaliza-
tion depending on the study design). Pulse pressure was defined as the
difference between systolic and diastolic pressure. The principal
outcome was all-cause mortality at 3 years from hospital discharge or
baseline study visit.
Statistical analysis
Measurementsof systolic anddiastolic BPwere available for patients in 22
of the31 studies included in theMAGGICmeta-analysis. This analysiswas
performed using data from these 22 studies (the full list of MAGGIC
studies is contained in Appendix section and those included in this
article are identified by *). Pulse pressure results were analysed in quin-
tiles and Cox proportional hazards models were used to estimate the
hazard of pulse pressure according to HF-PEF or HF-REF, adjusted for
the previously reported MAGGIC prognostic variables: age, gender, is-
chaemic aetiology, atrial fibrillation (AF), hypertension, and diabetes.
Mortality curves are similarly adjusted for the MAGGIC prognostic
variables. To further investigate the relationship with ejection fraction
(EF), those in the HF-REF group with a continuous measure of EF were
stratified as ,30 or 30–49%, and the adjusted model was repeated in
these groups. To investigate the independent prognostic significance of
pulse pressure and systolic BP, the main model was repeated using
these as continuous variables. The relationship between pulse pressure
and outcome in the presence of systolic blood pressure (SBP) was
evaluated with an interaction term for both HF-PEF and HF-REF.
Further analyses were performed in both EF groups, stratifying on SBP
,140/≥140 mmHg, using quintiles of pulse pressure. Sensitivity analyses
wereperformed: (i)withNewYorkHeartAssociation (NYHA)Class (I/II
vs. III/IV), (ii) withmedications [angiotensin-converting enzyme (ACE) in-
hibitor/angiotensin receptor antagonist, digoxin, and spironolactone],
(iii) excluding those patients with AF, and (iv) for acute HF vs. chronic
HF. A P-value of ,0.05 was considered statistically significant. Analyses
were performed using SAS v9.2 (SAS Institute, Inc.).
Results
Baseline characteristics according to
pulse pressure, overall
The 22 studies included 27 046 patients of whom 22 038 (81.5%)
had HF-REF. Complete data for 25 465 patients were available for
the multivariable analysis. Overall, the mean (SD) age was 65 (12)
years, 71% were male and median [inter-quartile ratio (IQR)]
LVEF was 34% (26, 45). Mean (SD) BP was 131 (23)/77 (12) mmHg,
resulting in a mean (SD) pulse pressure of 54 (18) mmHg. Table 1
shows the baseline characteristics of all patients according to quin-
tiles of pulse pressure. There were many differences between
patients according to pulse pressure value. Higher pulse pressure
was associated with older age, female sex, history of hypertension,
history of diabetes mellitus, higher systolic BP, and higher LVEF.
These differences were most marked in the highest pulse pressure
quintile, compared with the other quintiles. Those with a lower
pulse pressure were more likely to be male and younger, to have
had a previous myocardial infarction, to have a lower systolic and
diastolic BP, reduced LVEF and to be treated with an ACE inhibitor
or angiotensin receptor blocker, spironolactone, and digoxin; they
were less likely to have a history of diabetes and hypertension
(Table 1). Therewas no difference inb-blocker prescribing according
to pulse pressure.
Baseline characteristics according to
pulse pressure, by left ventricular ejection
fraction stratum
Of the 27 046 patients, 5008 (18.5%) patients had HF-PEF. The pro-
portion of patientswithHF-PEF increasedwith the higher quintiles of
pulse pressure: for example, 9% of the lowest quintile of pulse pres-
sure hadHF-PEF comparedwith 33% in the highest quintile (Table 1).
The mean (SD) pulse pressure was 52 (6) and 62 (4) mmHg for
patients with HF-REF and HF-PEF, respectively. Table 2 shows the
baseline characteristics according to quintiles of pulse pressure and
stratified according toHF-REF orHF-PEF. The differences in baseline
characteristics overall, described above, were also apparent within
each LVEF stratum.
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Distribution of pulse pressure by left
ventricular ejection fraction stratum
The proportion of patients with a pulse pressure ,45 mmHg dif-
fered considerably between those with HF-REF and HF-PEF
(Table 2). Of the 22 038 patients with HF-REF, 8802 (39.9%) had a
pulse pressure ,45 mmHg. Of 5008 patients with HF-PEF, 1025
(20.5%) had a pulse pressure ,45 mmHg. Conversely, 19.8 and
39.6% of patients with HF-REF and HF-PEF, respectively, had a
pulse pressure .65 mmHg.
All-cause mortality
During 3 years follow-up, there were 4980 (23%) and 828 (17%)
deaths among patients with HF-REF and HF-PEF, respectively.
There was a highly significant interaction between the EF category
(reduced/preserved) and the relationship between pulse pressure
and mortality (P, 0.0001).
In patients with HF-REF, crude mortality was highest in patients in
the lowest pulse pressure quintile although mortality differed little
across the other quintiles before adjustment for other prognostic
factors (Table 2). Mortality in Q1 (lowest) to Q5 (highest pulse pres-
sure) was 27, 21, 23, 22 and 24%, respectively. However, after
adjustment, there was a clear gradient in the risk of death according
to pulse pressure quintile with the highest risk in patients with the
lowest pulse pressure (Table 3, Figures 1 and 2). Compared with
patients in the highest quintile, those in the lowest pulse pressure
quintile had a 68% higher adjusted relative risk of death [95% confi-
dence interval (CI) 53–84%].
Analyses that further stratified the HF-REF group into those with
EF ,30 and 30–49% indicated that the increase in mortality asso-
ciated with low pulse pressure was particularly prominent among
patients with EF ,30% (see Supplementary material online, Tables
S1 and S2). For thepatientswithEF, 30%,mortalitywas significantly
higher for patients with a pulse pressure , 54 mmHg. When ana-
lysed as continuous variables, both pulse pressure and systolic BP
were independent predictors of mortality (data not shown).
However, therewas a significant interaction between pulse pressure
and systolic BP (P, 0.0001), and hence the size and direction of the
hazard ratio (HR) for each variable is difficult to interpret. To explore
this further, a stratified analysis based on SBP ,140/≥140 mmHg
was conducted and this showed that patients with both a lower sys-
tolic BP (,140 mmHg) and lowerpulse pressure seemed to farepar-
ticularly badly (Table 5).
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Table 1 Baseline characteristics according to groups defined by quintiles of pulse pressure
Pulse pressure (mmHg) Whole group ≤39 40–49 50–55 56–68 ≥69 P-value (test for trend)
n (22 studies) 25 465 4106 5957 4944 5352 5106 ,0.001
Age, years (SD) 65 (12) 60 (12) 63 (12) 65 (11) 67 (11) 70 (10) ,0.001
Women (%) 30 21 25 28 32 42 ,0.001
Medical history
Hypertension 47 32 38 44 54 66 ,0.001
Myocardial infarction 51 53 54 52 51 44 ,0.001
Atrial fibrillation 16 15 16 17 17 16 0.019
Diabetes 26 20 22 25 30 33 ,0.001
Ischaemic aetiology 60 59 63 61 61 57 ,0.001
Medication
ACEi or ARB 69 76 73 70 65 63 ,0.001
b-Blocker 43 43 45 43 43 42 0.039
Diuretic 79 82 79 80 77 80 0.009
Spironolactone 19 28 21 18 16 14 ,0.001
Digoxin 45 50 47 46 42 39 ,0.001
Clinical status
NYHA class (I or II/III or IV) 60/40 54/46 62/38 61/39 61/39 61/39
Heart rate (b.p.m.) 78 (17) 80 (17) 78 (16) 77 (16) 77 (16) 77 (17) ,0.001
SBP (mmHg) 131 (23) 106 (12) 118 (12) 128 (12) 128 (12) 160 (19) ,0.001
DBP (mmHg) 77 (13) 75 (11) 75 (11) 77 (12) 77 (12) 79 (15) ,0.001
Pulse pressure (mmHg) 54 (17) 31 (5) 42 (3) 51 (2) 51 (2) 80 (12) ,0.001
LVEF %, median (IQR) 34 (26, 45) 28 (21, 27) 32 (24, 40) 34 (26, 44) 34 (26, 44) 41 (31, 54) ,0.001
HF-PEF (%) 19 9 13 17 22 33 ,0.001
All-cause deaths, n (%) 5684 (22) 1071 (26) 1250 (21) 1033 (21) 1130 (21) 1200 (24) 0.029
Values in parentheses are standard deviations for continuous variables or percentages for discrete variables.
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; b.p.m., beats per minute; DBP, diastolic blood pressure; HF-PEF, heart failure with preserved
ejection fraction; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SBP, systolic blood pressure.
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Table 2 Baseline characteristics according to groups defined by quintiles of pulse pressure, in patients with reduced and preserved EF
HF-REF P-value
(test for trend)
HF-PEF P-value
(test for trend)
Pulse pressure (mmHg) ≤39 40–45 46–53 54–64 ≥64.5 ≤45 46–55 56–64 65–78 79–164
n (22 studies) 3750 4455 4011 4324 4118 966 978 938 962 963
Age, years (SD) 60 (12) 62 (12) 65 (11) 67 (10) 69 (10) ,0.001 65 (13) 67 (12) 69 (11) 71 (10) 73 (10) ,0.001
Women (%) 19 22 25 26 34 ,0.001 39 45 46 53 61 ,0.001
Medical history
Hypertension 31 34 42 50 60 ,0.001 47 56 64 71 78 ,0.001
MI 55 57 56 56 51 ,0.001 33 34 30 32 30 0.030
Atrial fibrillation 14 15 15 16 14 0.456 26 26 24 24 17 ,0.001
Diabetes 20 21 25 30 32 ,0.001 19 23 28 30 35 ,0.001
Ischaemic aetiology 60 65 63 65 62 ,0.001 50 51 48 48 49 0.219
Medication
ACEi or ARB 79 78 76 72 70 ,0.001 44 44 44 42 53 0.001
Beta-blocker 42 44 44 43 42 0.369 46 45 42 43 41 0.016
Diuretic 83 80 81 79 81 0.047 72 73 74 75 78 0.001
Spironolactone 29 22 20 18 14 ,0.001 17 13 14 15 10 ,0.001
Digoxin 51 50 50 46 44 ,0.001 30 31 28 31 27 0.108
Clinical status
NYHA class (I or II/III or IV) 54/46 59/41 60/40 61/39 60/40 ,0.001 67/33 69/31 65/35 62/38 63/37 ,0.001
Heart rate (b.p.m.) 80 (17) 77 (16) 77 (16) 77 (16) 78 (17) ,0.001 77 (18) 76 (17) 77 (18) 75 (17) 77 (20) ,0.001
SBP (mmHg) 106 (12) 116 (11) 126 (12) 136 (12) 156 (18) ,0.001 115 (14) 129 (12) 131 (20) 150 (13) 172 (22) ,0.001
DBP (mmHg) 75 (11) 75 (11) 76 (12) 77 (12) 79 (14) ,0.001 77 (12) 78 (12) 79 (13) 79 (13) 80 (17) ,0.001
Pulse pressure (mmHg) 31 (5) 41 (2) 50 (1) 59 (3) 77 (11) ,0.001 38 (6) 51 (2) 60 (2) 70 (3) 92 (14) ,0.001
LVEF %, median (IQR) 27 (20, 34) 30 (23, 37) 32 (24, 38) 33 (26, 39) 34 (27, 41) ,0.001 58 (53, 63) 58 (53, 64) 59 (54, 64) 59 (54, 66) 60 (55, 66) ,0.001
All-cause deaths, n (%) 1017 (27) 952 (21) 919 (23) 971 (22) 1007 (24) 0.046 128 (13) 142 (14) 153 (16) 175 (18) 220 (22) ,0.001
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In contrast to the patients with HF-REF, crude mortality among
patientswithHF-PEFwashighest in those in thehighestpulsepressure
quintile and there appeared to be a gradient in crudemortality across
the other quintiles before adjustment for other prognostic factors
(Table 2). Crude mortality in Q1 (lowest) to Q5 (highest pulse pres-
sure) was 13, 14, 16, 18 and 22%, respectively. After adjustment,
however, the gradient in risk according to pulse pressure quintile in
patients with HF-PEF was largely eliminated (Table 4, Figures 1 and
2). Compared with patients in the highest quintile, those in quintiles
2, 3, and 4 had an adjusted HR of 1.0. Those in the lowest quintile
had an adjustedHRof 1.16 (95%CI 0.92, 1.45). In a similar manner to
the analysis for patients with HF-REF, we explored this further with a
stratified analysis based on SBP ,140/≥140 mmHg, which showed
that there was no significant interaction between the pulse pressure
(quintiles) and the BP groups (Table 5).
WhenNYHAclasswas included in themodel (see Supplementary
material online, Tables S3 and S4), higher NYHA class (III/IV) was
associated with worse outcome [HF-REF: HR 1.87 (95% CI 1.76,
2.00); HF-PEF HR 1.99 (95% CI 1.69, 2.34)]. In patients with
HF-REF, low pulse pressure remained an indepedent predictor of
death even taking account of NYHA class. The relationship
between pulse pressure andmortality was not alteredwhen analyses
were repeatedwith the addition of ACE inhibitor/angiotensin recep-
tor antagonist, digoxin, and spironolactone treatment.
When analyseswere re-run excluding patientswithAF: the results
for thosewithHF-REFwere similar to themain analyses (see Supple-
mentarymaterial online, Tables S5 and S6). The results for thosewith
HF-PEF demonstrate that those patients with the lowest pulse pres-
sure quintile were at increased risk (HR for lowest quintile of pulse
pressure 1.33, 95% CI 1.02, 1.73).
Acute heart failure vs. chronic heart failure
The multivariable models were repeated for patients with acute HF
only (see Supplementary material online, Tables S7 and S8). A very
similar pattern of findings was apparent although, with the reduced
numbers (4746 patients compared with 25 465 for the main
models) and power in this subset, mortality was significantly higher
only in the lowest pulse pressure quintile in patients with HF-REF.
Interestingly, in patients with acute HF-PEF, there was an increased
risk with pulse pressure, 56 mmHg, although the lowest quintile
group (≤45 mmHg) was of borderline significance (P ¼ 0.049).
The multivariable analyses were also performed for patients with
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Multivariable model by quintiles of pulse
pressure in 20 658 patients with HF-REF—adjusted for
the Meta-Analysis Global Group in Chronic Heart
Failure variables
Variable HR (95% CI) P-value
Pulse pressure (mmHg)
≥64.5 1
54–64 1.02 (0.93, 1.11) 0.749
46–53 1.15 (1.05, 1.26) 0.003
40–45 1.23 (1.12, 1.35) ,0.001
≤39 1.68 (1.53, 1.84) ,0.001
Age (per year increase) 1.04 (1.03, 1.04) ,0.001
Gender (male) 1.21 (1.13, 1.29) ,0.001
Atrial fibrillation 1.21 (1.12, 1.32) ,0.001
Hypertension 0.99 (0.93, 1.05) 0.608
Ischaemic aetiology 1.12 (1.05, 1.19) 0.001
Diabetes 1.47 (1.38, 1.56) ,0.001
Figure 1 Quintiles of pulse pressure by ejection fraction group. Adjusted for age, gender, hypertension, atrial fibrillation, ischaemic aetiology,
and diabetes.
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chronic HF only (see Supplementary material online, Tables S9 and
S10). The findings were consistent with the overall model.
Discussion
This largemeta-analysis is thefirst study todescribe the rangeofpulse
pressure and evaluate the prognostic significance of pulse pressure in
patients with HF-PEF, as well as patients with HF-REF. The physio-
logical influences on pulse pressure in HF are complex and appear
to be dependent on EF, with left ventricular function and stroke
volume playing an important role in HF-REF. This is in contrast to
HF-PEF where the major influence on pulse pressure is probably
arterial stiffness. As has been described previously, HF-REF patients
in the lowestpulsepressurequintilehad thehighest crudeandadjusted
mortality risk, compared with all other pulse pressure groups.
However, the relationship among patients with HF-PEF differed:
while the highest pulse pressure quintile had the highest crude mor-
tality, this difference did not persist in the multivariable analyses.
Association between lower pulse pressure
in HF-REF and increased mortality
Paradoxically, the relationship between pulse pressure andmortality
appears to be reversed in HF-REF compared with that seen in
patients with other cardiovascular diseases and among individuals
in thegeneral populationwhereahighpulsepressurehas consistently
been linked to adverse outcomes. In populations where high pulse
pressure predicts mortality risk, the cause of high pulse pressure is
thought to be reduced aortic elasticity secondary to arteriosclerosis
and the increased risk possibly reflects widespread arteriosclerotic
disease.11,12 However, a different pathophysiological process is
evident in HF-REF where a lower pulse pressure is not an index of
arterial stiffness but represents reduced cardiac function and lower
stroke volume. This has recently been confirmed in an analysis
from the Eplerenone Post-Acute Myocardial Infarction Heart
Failure Efficacy and Survival Study (EPHESUS).13 In a sub-study in
these patients with HF-REF after myocardial infarction, pulse
Figure2 Mortality curvesof pulsepressurequintilesbyejection fraction group.Adjusted forage, gender, hypertension, atrial fibrillation, ischaemic
aetiology, and diabetes. The curves for the pulse pressure groups of the middle three quintiles (46–55, 56–64, and 65–78 mmHg) overlap, with
lower mortality compared with the highest and lowest quintiles.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Multivariable model by quintiles of pulse
pressure in 4807 patients with HF-PEF—adjusted for the
Meta-Analysis Global Group in Chronic Heart Failure
variables
Variable HR (95% CI) P–value
Pulse pressure (mmHg)
≥79 1
65–78 1.01 (0.82, 1.23) 0.959
56–64 0.98 (0.79, 1.21) 0.836
46–55 0.98 (0.79, 1.22) 0.857
≤45 1.16 (0.92, 1.45) 0.219
Age (per year increase) 1.06 (1.05, 1.07) ,0.001
Gender (male) 1.36 (1.18, 1.57) ,0.001
Atrial fibrillation 1.15 (0.96, 1.37) 0.130
Hypertension 1.00 (0.86, 1.17) 0.977
Ischaemic aetiology 1.04 (0.90, 1.20) 0.609
Diabetes 1.61 (1.39, 1.87) ,0.001
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pressure was more dependent on left ventricular function and was
not a marker of aortic stiffness, as measured by carotid-femoral
pulse wave velocity. Low proportional pulse pressure (pulse pres-
sure/systolic BP) has previously shown a correlation with a low
cardiac index and stroke volume index in patients with advanced
HF-REF.14 However, the paradox in patients with HF-REF does not
seem to be explained solely by measures of systolic function as
studies of patients with asymptomatic left ventricular systolic dys-
function (LVSD)15,16 have shownhigh pulse pressure to be predictive
of mortality risk. This seems to indicate that the transition to symp-
tomatic HF-REF in some way reverses the usual relationship
between pulse pressure and outcome. Lower pulse pressure has
also been associated with higher B-type natriuretic peptides
(BNPs) in advanced HF-REF.5 An additional finding in this study is
that the risk associated with low pulse pressure in patients with
HF-REF is especially marked in those with a lower SBP. The relation-
ship between severity of LVSD, SBP, and outcome is complex. There
is a U-shaped association between SBP and outcome in patients with
less severe LVSD whereas in patients with more severe LVSD the
relationship is linear, with lower SBP associated with increased
mortality risk.17 One possible (but speculative) explanation for our
finding of increased mortality risk in those with low pulse pressure
and lower SBP is that both of these together identify patients with
a particularly low stroke volume who are at greatest mortality risk.
Pulse pressure in HF-PEF and outcome: a
reverse pattern compared with HF-REF
The relationship between pulse pressure andmortality appears to be
completely different among patients with HF-PEF. Analysis of crude
mortality showed the reverse pattern to that observed in HF-REF,
with the highest risk in those with the highest pulse pressure. At
first sight this might seem to make sense as patients with HF-PEF
are ‘phenotypically’ more similar to subjects with hypertension, or
even elderly individuals in the general population, both of which
have worse outcomes with higher pulse pressure. A recent analysis
from the Aldosterone Receptor Blockade in Diastolic Heart Failure
trial showed that higher pulse pressure was associated with higher
E/E′, an index of increased left ventricular filling pressure and more
severe diastolic dysfunction.18 Higher pulse pressure may be a
crude surrogate of increased arterial stiffness. Increased arterial stiff-
ness increases afterload and cardiacwork andmechanistically there is
a plausible link between high pulse pressure and the development of
HF-PEF.However, the associationbetween increasing pulse pressure
and increasing mortality was eliminated by adjustment for other
prognostic variables (whereas the association between pulse pres-
sure and mortality was strengthened by adjustment in HF-REF).
The loss of this association highlights the complexity of the condition
of HF-PEF and the prognostic importance of the underlying co-
morbidities in the outcomes for patientswithHF-PEF. The difference
between crude and adjusted risk seemed to reflect the high propor-
tion of women (61% vs. 39%) and patients with diabetes (35% vs.
19%) in the highest pulse pressure quintiles compared with the
lowest pulse pressure quintiles, two of themost powerful prognostic
variables in these patients. The highest quintile also had a particularly
low proportion of patients with AF and high proportion of patients
with hypertension, although these were not significant predictors
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ofmortality. Several of the prognostic variables included in themulti-
variable model are recognized determinants of arterial stiffness (e.g.
age, sex, history of hypertension, and diabetes) and thus adjustment
for these may have eliminated the significance of pulse pressure as a
surrogate for arterial stiffness in HF-PEF. For patients with HF-PEF,
therefore, higher pulse pressure may reflect more arterial stiffness
and truly related tohighermortality. In a recent retrospective analysis
of results from the Digitalis Investigator Group (DIG) trial,19 there
was a significant J-shaped relationship between pulse pressure and
mortality. Interestingly in our more contemporary population of
patients with HF-PEF, we found the crude mortality was highest
among patients in the highest quintile (Table 2). However, there
was no difference across the quintiles on multivariable analysis.
However, in two sub-groups of patients with HF-PEF (acute HF
and patients without AF), lower pulse pressure was an independent
predictor of mortality. While sub-group findings must always be
interpreted with caution, lower pulse pressure in these patients
may also be an index of lower stroke volume. Reduced stroke
volume has previously been reported in HF-PEF20 and this may
explain the J-shape relationship between pulse pressure and mortal-
ity seen in the retrospective analysis from theDIG trial.19 These find-
ings should be explored further in future, larger studies.
The finding of a low prevalence of AF in the highest pulse pressure
quintile is curious, if not paradoxical. Higher pulse pressure is a pre-
dictor of incident AF in the general population and in patients with
certain types of cardiovascular disease.21,22 Yet we saw the opposite
in relation to prevalence in patients withHF-PEF. This does not seem
to be explained by difficulty in measuring pulse pressure in patients
with AF as no such variation in prevalence of AFwas found according
to pulse pressure quintile in patients with HF-REF.
Limitations
This meta-analysis incorporated data from a large number of obser-
vational studies and randomized clinical trials, and therefore, BPmea-
surements were not performed in a standardized fashion. Another
limitation resulting from the use of a large number of observational
studies and randomized clinical trials is the lack of standardization
of HF diagnosis. As previously described, the variables that were
incorporated into the multivariable model were selected due to
their clinical relevance and because they were available in the major-
ity of patients. Other variables, which may have prognostic signifi-
cance, were not included due to the amount of missing data.
Therefore, the multivariable model did not include established bio-
markers, such as renal function, sodium, and haemoglobin or power-
ful contemporary biomarkers such as BNP. Future work should
incorporate such biomarkers to evaluate the incremental prognostic
value of pulse pressure. Pulse pressuremay changewithin short time
intervals andmeanpulsepressureover severalmeasurements, rather
than a single measurement, may provide additional prognostic infor-
mation. Central pulse pressure has been demonstrated to be a stron-
ger prognostic marker than brachial pulse pressure in patients with
hypertension23; however, this has never been measured in any
large-scale trial in HF and was not available from any of the studies
included in our analyses. A recent sub-study of EPHESUS13 found
aortic pulse wave velocity, measured by carotid-femoral pulse
wave velocity, to be predictive of increased risk of cardiovascular
death. The latter, a marker of increased aortic stiffness, was not
available in this study but should be included in future research.
Finally, the only clinical outcome available in the majority of studies
was all-causemortality andwewere not able to look at non-fatal out-
comes.
Conclusions
Pulse pressure is a simple, inexpensive, and readily available clinical
index. This non-invasive test provides useful prognostic information
for patients with HF-REF (particularly in those with an LVEF, 30%)
where lower pulse pressure (especially ,53 mmHg) independently
predicts mortality, particularly in patients with lower systolic BP
(,140 mmHg). The prognostic utility of pulse pressure among
patients with HF-PEF appearsmore complex, with higher pulse pres-
sure appearing to be predictive of crude but not adjusted mortality.
Future analyses evaluating the incremental prognostic value of
pulse pressure, in addition to powerful contemporary biomarkers
in HF, are required to determine if this simple clinical sign has a role
in HF risk stratification. Such studies should include patients with
HF-PEF as well as HF-REF.
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Supplementary material is available at European Heart Journal online.
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